Do you want to read an article? Please log in or register.
Chronic Lymphocytic Leukemia
Leukemia
ASH 2020
Related content
RECOMMENDED
Leukemia
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1182/blood.2019003453.
Leukemia
Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia
Leukemia.
Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR
doi: 10.1038/leu.2017.34.
LeukemiaLymphoma
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length
Leuk Lymphoma.
Ammann EM, Shanafelt TD, Wright KB, McDowell BD, Link BK, Chrischilles EA
doi: 10.1080/
Leukemia
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
Leukemia.
Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F
doi: 10.1038/leu.2016.359
Leukemia
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
doi: 10.3324/haematol.2018.187583.
EHA® 25 Virtual
Lymphoma
Chronic Lymphocytic Leukemia
Siddiqi et al. 2020. First-line ibrutinib (IBR) + venetoclax (VEN) for patients (PTS) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): efficacy and safety results from CAPTIVATE MRD cohort.
Oral presentation presented at: EHA25 VIRTUAL; 11−21 June 2020.
Leukemia
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)
Haematologica.
Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Michael Hallek, Hartmut Döhner, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, Stephan Stilgenbauer
doi: 10.3324/haematol.2019.231027.
EHA® 25 Virtual
Further Publications
Chronic Lymphocytic Leukemia
Al-Sawaf, O. et al. 2020. Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: follow-up of efficacy and safety results from the multicenter, open-label, randomized phase III CLL14 trial. Oral presentation presented at: EHA25 Virtual; 11−21 June 2020.
Leukemia
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study
Haematologica.
Mato AR, Sharman JP, Biondo JML, Wu M, Mun Y, Kim SY, Humphrey K, Boyer M, Zhu Q, Seymour JF
doi: 10.3324/haematol.2020.266486.